Navigating the New Normal:

CARE™ CLL Guidance 2021

Hematology

26 Jan 2021

In July 2020, The CARE™ Hematology Faculty developed and published Considerations for Malignant Hematology Patient Management and Treatment During the COVID-19 Era.

Changes in the delivery of care brought on by the pandemic have happened fast, despite not necessarily being optimal for patient outcomes. These changes, as well as recent drug approvals have prompted the CARE™ Faculty to update the CARE™ CLL Treatment Guidance; first developed and distributed in 2018.

This is the 3rd iteration (V.3) of the CARE™ CLL Treatment Guidance. It aims to provide further context and guidance specifically on management of CLL as clinicians navigate the new normal in 2021.

Click here to view the CLL Guidance

CARE™ Supplement CLL Case Study Series

Welcome to the 4th issue in the CARE™ CLL Case Study Series. This series provides context and guidance on how to navigate some of the challenges that specialists may face in routine practice. Issue 4 explores Successful Initiation of Venetoclax (Ven) + Rituximab (R) in Outpatient Setting. Profile and discussion follow.

Click here to view Issue 4

Other Issues in the Series:

Issue 1 (Parts 1 & 2) explored identification and management of relapse after BTK inhibition. These publications are also available for download.
Visit Issue 1
Issue 2 focuses on management of relapse after up-front chemoimmunotherapy. Profile and discussion content follows.
Visit Issue 2
Issue 3 focuses on appropriate prevention of tumour lysis syndrome (TLS) with a modified titration schedule for starting patients on venetoclax. Profile and discussion content follows.
Visit Issue 3